ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Other Liabilities
ADC Therapeutics SA
Other Liabilities Peer Comparison
Competitive Other Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Other Liabilities
$8.9m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Other Liabilities
CHf5.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Other Liabilities
$238m
|
CAGR 3-Years
51%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Other Liabilities
CHf40.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-13%
|
|
Idorsia Ltd
SIX:IDIA
|
Other Liabilities
CHf258.5m
|
CAGR 3-Years
24%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Other Liabilities
CHf0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Other Liabilities?
Other Liabilities
8.9m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Other Liabilities amounts to 8.9m USD.
What is ADC Therapeutics SA's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
35%
Over the last year, the Other Liabilities growth was -65%. The average annual Other Liabilities growth rates for ADC Therapeutics SA have been -55% over the past three years , 35% over the past five years .